Introduction
Acute myeloid leukaemia (AML) with megakaryoblastic differentiation represents a rare subtype of AML which tends to present with myelofibrosis and has a poor prognosis. 1, 2 In childhood, most cases are associated with Down's syndrome (trisomy 21) or display the t(1;22)(p13;q13) abnormality. 2 In many instances, bone marrow biopsy is required for diagnosis due to extensive myelofibrosis. The differential diagnoses encompass acute panmyelosis with myelofibrosis and either primary or secondary myelodysplastic syndromes (MDS) with excess of blasts and myelofibrosis. 2 In addition, secondary AML evolving from chronic myeloproliferative disorders/myeloproliferative neoplasms (CMPD), particularly primary myelofibrosis (PMF) have to be excluded. Other AML subtypes, for example, MDS-related AML with multilineage dysplasia, may also be associated with myelofibrosis.
The myeloproliferative leukaemia virus proto-oncogene/ thrombopoietin receptor (MPL) promotes both proliferation and differentiation of non-neoplastic megakaryocytes. It is expressed in several AML subtypes, including megakaryoblastic AML and can be involved in aberrant signal transduction in acute leukomogenesis, for example, by mediating a hypersensitivity of blast cells to thrombopoietin. 3 The thrombopoietin gene is located on chromosome 3q27-28 but appears not to be involved in the inversion 3q21q26, which can be found in AML with a megakaryoblastic phenotype associated with thrombocytosis. 4 Most recently, the first systematic search for MPL mutation in acute megakaryoblastic leukaemia has been undertaken and has revealed one single case with a MPL T487A mutation. 5 MPL gain of function point mutations (MPL W515K/L ) have been described in Philadelphia chromosome-negative (Ph À ) CMPD, comprising PMF (B5% MPL mutated) and essential thrombocythemia (ET; B1% MPL mutated). 6 More frequently than MPL W515K/L the Janus kinase 2 point mutation (JAK2 V617F ) is detectable in B95% of polycythemia vera and B60% of PMF and ET cases. 7 Screening for MPL W515K/L and JAK2 V617F in a representative number of 126 AML cases revealed that 23% were JAK2 V617F -positive, but only 2% of post-PMF AML or post-ET AML cases without megakaryoblastic phenotype were MPL W515K/L mutated. 6 Further studies on AML, mostly de novo cases, have been undertaken and only 5/60 (8%) megakaryoblastic AML were JAK2 V617F -mutated, whereas MPL W515K/L had not been tested. 3, [8] [9] [10] In this study, MPL W515L (but not JAK2
V617F
) was detected in about 25% of AML with a megakaryoblastic phenotype and myelofibrosis, including an MPL W515L -mutated blast crisis of Ph þ chronic myeloid leukaemia (CML), which has not previously been described.
Materials and methods

Study group
Archived, formalin-fixed and paraffin-embedded (FFPE) bone marrow trephines from 21 patients were included in the study. The study comprises 13 cases of primary or secondary AML with a megakaryoblastic phenotype in more than 50% of the blasts and myelofibrosis. In 12 cases, evidence of antecedent PMF could be excluded, whereas one case had a history of PMF. In addition, for control purposes, seven cases of primary or secondary AML with myelofibrosis, but with a blast population without any markers of megakaryocytic lineage, and one biphasic myeloperoxidase þ /CD61 þ AML with myelofibrosis, were studied. All but one sample were collected as part of the standard clinical care for evaluation of bone marrow status (diagnosed between 1990 and 2008) and were subsequently archived in the Institute of Pathology, Hannover Medical School. Consistent with the requirements of our local ethics committee and patient's approval for biopsy, storage and research use, after diagnosis had been established, archived samples were considered to be remnant material unnecessary for patient treatment. The sample from patient no. 2 was submitted by the Department of Pathology, Karolinska Hospital, Stockholm, Sweden, for consultation.
Megakaryoblastic phenotype was verified by immunostaining of megakaryocyte/platelet-specific antibodies (mouse anti-CD42b antibody, clone MM2/174 (Novocastra, Newcastle upon Tyne, UK); mouse anti-CD61 antibody, clone Y2/51 and mouse anti-von Willebrand factor/factorVIII antibody, clone F8/86 (both Dako, Glostrup, Denmark)) and CD34 (mouse anti-CD34 antidody, clone QBEND/10; Immunotech, Praha, Czech Republic). No corresponding peripheral blood and due to myelofibrosis ('dry tap') no bone marrow aspirate had been archived for retrospective evaluation.
Determination of MPL
W515K/L and JAK2 V617F allele burden in bone marrow cells DNA aliquots from FFPE bone marrow cells (DNeasy kit; Qiagen, Hilden, Germany) were used for PCR amplification of MPL and JAK2 fragments, which included the mutation sites and subsequent pyrosequencing (Biotage, Uppsala, Sweden) as described. 8 In brief, the specific sequencing primer binds to its corresponding PCR fragment, shortly before the mutation site, and in a second step pyrophosphate nucleotides are injected into the reaction tube. Incorporation of the wild-type or, in a subsequent reaction, the mutant nucleotide results in pyrophosphate release, which activates a connected luciferase-enzyme cascade. The resulting light signal is proportional to the amount of incorporated wild-type or mutant nucleotides and allows a quantification of alleles. All samples were analysed in duplicate (controls: JAK2 V617F cell line HEL, MPL-mutated PMF, JAK2/ MPL-unmutated cell line HL-60). The following primer sets were used: JAK2-forward 5
0 , 79 bp PCR products; MPLsequencing 5 0 -TGCTGCTGCTGAGGT-3 0 (GenBank U68161). In a series of eight bone marrow samples not related to this study parallel pyrosequencing in formalin-fixed and fresh frozen tissue samples yielded similar results (data not shown).
Laser microdissection and analysis of megakaryocytic blasts
In Ph þ /MPL W515L double-mutated case (patient no. 3), B150 dysplastic megakaryocytes and megakaryoblasts were laser microdissected from 4 mm bone marrow sections with a SmartCutPlus-System (Olympus, Hamburg, Germany) as depicted in Figure 1 and DNA was analysed for mutant MPL by pyrosequencing. In addition, RNA from laser-microdissected megakaryocytic cells was extracted from a corresponding section (proteinase K digestion followed by phenol/chloroform extraction and isopropanol precipitation), 1 mg was pretreated with RNase-free DNase (1 U/mg RNA; RQ1; Promega, Madison, WI, USA) and transcribed into cDNA (500 ng random hexamers; Amersham Pharmacia, Picattaway, CA, USA; 200 U SuperScript II Rnase-free Reverse Transcriptase; Invitrogen, Karlsruhe, Germany). 11 Verification of sufficient cDNA synthesis was performed by amplification of control gene b-glucuronidase
0 -CACTTTTTGGTTGTCTCTGCCG-3 0 ; 81 bp PCR products; GenBank NM000181). As indicated by previous analysis of the corresponding bone marrow cells, the megakaryocytic cDNA sample was analysed for BCR-ABL fusion b3a2 with the following primer set: BCR-b3-forward 5 0 -GAGTCTCCGG GCTCTATGG-3 0 , ABL-a2-reverse 5 0 -TCAGATGCTACTGGCC GCTGAA-3 0 (98 bp b3a2 fusion products; GenBank AJ131466; control cell line K 562).
Statistical analyses
Megakaryoblastic AML cases were grouped according to their MPL mutation status and were statistically analysed for differences in clinical parameters at AML presentation. Oneway analysis of variance was performed (two-tailed). P-values p0.05 were considered as statistically significant.
Results and discussion
Compared to the rather low frequency of MPL W515K/L in PMF (B5%), 6 AML cases with megakaryoblastic differentiation and myelofibrosis but no evidence of a pre-existing PMF revealed a higher frequency of MPL W515L (3/12, 25%, Table 1 ). JAK2 V617F which affects 60-95% of Ph À CMPD, 7, 8 was not detected. Of eight studied cases with pre-existing PMF and secondary AML with myelofibrosis, two were positive for JAK2 V617F and devoid of MPL W515K/L (no. 15, no. 16). Furthermore, the MPL W515L mutation was detectable in one AML secondary to MDS with myelofibrosis but without evidence of a megakaryoblastic differentiation or an antecedent PMF (no. 14). In the cohort under investigation, MPL W515K was not detected. Thus, none of the four MPL W515L -positive AML cases with myelofibrosis had evidence of a previous PMF preceding the AML and three of these cases had a megakaryoblastic differentiation. Based on our limited cohort, the frequency of MPL W515L -positive cases in AML with myelofibrosis seems to be fourfold higher than in PMF (4/21, 19%).
None of the remaining seven cases with primary or secondary AML and myelofibrosis and with a blast population not belonging to the megakaryocytic lineage revealed MPL W515K/L mutation.
None of the four MPL W515L -positive AML cases had evidence of a previous PMF or ET preceding AML. In patient no. 1, megakaryoblastic AML was the initial disease presentation, Figure 1 Laser microdissection of dysplastic megakaryocytes and megakaryoblasts in MPL W515L acute myeloid leukaemia (AML). The laser microdissection of a megakaryocytic cell from a bone marrow section of patient no. 3 is depicted (methylene blue stain, original magnification Â 400; SmartCutPlus-System based on a CKX41 inverse microscope, Olympus). Abbreviations:~, female; #, male; À, no myelofibrosis; +, myelofibrosis; AML, acute myeloid leukaemia; BM, bone marrow blast; CML, chronic myeloid leukaemia; FLT3/ITR + , FMS-Like-Tyrosine kinase-3 internal tandem repeat; HB, haemoglobin; HIV, human immunodeficiency virus; LDH, lactate dehydrogenase; MDS, myelodysplastic syndrome; MK, laser-microdissected megakaryoblasts; ND, not determined/data not available; PB, peripheral blood blasts; PLT, platelet counts; PMF, primary myelofibrosis; WBC, white blood cell counts; WT, wild-type at mutation site. Haematological parameters, particularly platelet counts, were not significantly altered by an underlying MPL W515L mutation. Karyotype no. 5: 47,XX t(X;9)(p10;p10), +21 [7] /46,XX [10] . were detectable in cDNA and DNA, respectively, isolated from all bone marrow cells. After microdissection of megakaryoblasts it became obvious that this blast population did not share the Ph þ abnormality but exhibited only MPL W515L mutation. Although loss of the Philadelphia chromosome during clonal evolution of blast crisis cannot be excluded, development of a second malignant clone rather than clonal evolution of the existing one, appeared to be responsible for the megakaryoblastic MPL W515L -positive blast crisis. Coexistence of mutations of growth regulatory genes, which are usually sufficient to transform haematopoietic cells alone have been described before in CMPD. It remains a matter of debate, whether one double-mutated or two independent clones are the basis of neoplastic growth in these types of CMPD. 13, 14 In conclusion, (1) MPL W515L mutation can be detected in bone marrow samples of megakaryoblastic AML with myelofibrosis unrelated to classical PMF and (2) MPL W515L can occur in megakaryoblastic blast crisis of CML.
